AU2001232787A1 - Airway alkalinization as therapy for airway diseases - Google Patents

Airway alkalinization as therapy for airway diseases

Info

Publication number
AU2001232787A1
AU2001232787A1 AU2001232787A AU3278701A AU2001232787A1 AU 2001232787 A1 AU2001232787 A1 AU 2001232787A1 AU 2001232787 A AU2001232787 A AU 2001232787A AU 3278701 A AU3278701 A AU 3278701A AU 2001232787 A1 AU2001232787 A1 AU 2001232787A1
Authority
AU
Australia
Prior art keywords
airway
alkalinization
therapy
diseases
airway diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232787A
Inventor
Benjamin M. Gaston Iv
John F. Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Publication of AU2001232787A1 publication Critical patent/AU2001232787A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001232787A 2000-01-14 2001-01-12 Airway alkalinization as therapy for airway diseases Abandoned AU2001232787A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17638800P 2000-01-14 2000-01-14
US60176388 2000-01-14
PCT/US2001/001062 WO2001051046A1 (en) 2000-01-14 2001-01-12 Airway alkalinization as therapy for airway diseases

Publications (1)

Publication Number Publication Date
AU2001232787A1 true AU2001232787A1 (en) 2001-07-24

Family

ID=22644157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232787A Abandoned AU2001232787A1 (en) 2000-01-14 2001-01-12 Airway alkalinization as therapy for airway diseases

Country Status (4)

Country Link
US (5) US6930125B2 (en)
AU (1) AU2001232787A1 (en)
CA (1) CA2396165C (en)
WO (1) WO2001051046A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2002082977A2 (en) * 2001-04-17 2002-10-24 University Of Virginia Patent Foundation Breath test for assessing diseases, particularly asthma
ATE311181T1 (en) * 2001-07-16 2005-12-15 Greenhills Biotechnology Res D USE OF AN ANTIVIRAL CLASS OF COMPOUNDS (DITHIOCARBAMAT COMPOUNDS) FOR THE PRODUCTION OF A TREATMENT AGENT. PREVENTION OF VIRUS INFECTION IN THE RESPIRATORY TRACT
US7101341B2 (en) * 2003-04-15 2006-09-05 Ross Tsukashima Respiratory monitoring, diagnostic and therapeutic system
US7166201B2 (en) 2003-12-01 2007-01-23 Sierra Medical Technology Self-condensing pH sensor
EP1962869B1 (en) * 2005-12-21 2013-03-20 SolAeroMed Inc. Treatment of respiratory diseases
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
US20100081954A1 (en) * 2008-09-30 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and system to control pH in pulmonary tissue of a subject
CN102573886A (en) * 2009-09-17 2012-07-11 相互制药公司 Method of treating asthma with antiviral agents
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
JP2020040924A (en) * 2018-09-13 2020-03-19 学校法人慶應義塾 Group 2 innate lymphoid cell (ilc2) activity inhibitor containing disulfiram
US11638722B2 (en) 2020-03-25 2023-05-02 Therapeutica Borealis Oy C/O Avance Attorneys Ltd. Medicine for Covid-19 and treatment
US11278602B2 (en) 2020-03-25 2022-03-22 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
US11007187B1 (en) * 2020-03-25 2021-05-18 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
WO2021207155A1 (en) * 2020-04-06 2021-10-14 The Trustees Of Indiana University Airway epithelial alkaline therapy to treat viral respiratory infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008454T2 (en) * 1989-08-07 1994-08-25 Takeda Chemical Industries Ltd Nitrolsothiol derivatives, their production and use.
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
KR19980703876A (en) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 Powdered pharmaceutical compositions with improved dispersibility
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
ATE224718T1 (en) * 1996-06-25 2002-10-15 Cephalon Inc USE OF A K-252A DERIVATIVE TO TREAT PERIPHERAL OR CENTRAL NERVOUS DISEASES AND EXCESSIVE CYTOKINE PRODUCTION
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5906611A (en) * 1997-07-28 1999-05-25 Dodick; Jack Murray Surgical instrument with laser target
KR20010031363A (en) * 1997-10-22 2001-04-16 젠스 포니카우 Use of antifungal agents for the topical treatment of fungus-induced mucositis
US6723703B2 (en) * 2000-10-16 2004-04-20 Duke University Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis

Also Published As

Publication number Publication date
CA2396165C (en) 2011-01-04
US20070134166A1 (en) 2007-06-14
US6930125B2 (en) 2005-08-16
CA2396165A1 (en) 2001-07-19
WO2001051046A1 (en) 2001-07-19
US20070128126A1 (en) 2007-06-07
US20090054384A1 (en) 2009-02-26
US20050222103A1 (en) 2005-10-06
US20030013695A1 (en) 2003-01-16
US7888385B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2002341931A1 (en) Patient directed therapy management
AU2002222853A1 (en) Therapeutic compounds
AU2002343739A1 (en) Improved therapy for topical diseases
AU2001252135A1 (en) Therapeutic agents
AU2003289997A1 (en) Inhalation therapy device
AU2002226650A1 (en) Redox therapy for tumors
AU2001232787A1 (en) Airway alkalinization as therapy for airway diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU6900201A (en) Breath-controlled therapeutic inhalation device
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU2003247005A1 (en) Therapy combination
AU2001243515A1 (en) Combination drug therapy
AU2002353739A1 (en) Therapeutic compounds
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003244638A1 (en) Inhalation therapy device
AU2002335667A1 (en) Modified reoviral therapy
AU2001286341A1 (en) Therapeutic bio-energy unit
AU2001273903A1 (en) Therapeutic agents
AU2001271999A1 (en) Therapeutic uses for aminosterol compounds
AU2000231423A1 (en) Specific therapeutic composition for treating aids
AU1405001A (en) Treatment of diseases
AU2001275696A1 (en) Therapeutic agent
AU3567500A (en) Photodynamic therapy compounds
AU2001264375A1 (en) Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photocynamic therapy